Melanoma (primary nd

Melanoma (primary nd

Contact us: [email protected]

Melanoma Tissue Array - 12 cases of normal epithelium, nevus, and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates.
Z7020108 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Human Melanoma Primer Library
HMEL-I 1 set
EUR 657.6

Melanoma Tissue Slide (Skin- Melanoma)
12-801-10um 10 um
EUR 241.8

Melanoma Tissue Slide (Skin- Melanoma)
12-801-4um 4 um
EUR 216.6

Primary UTI
MED1270 PK10
EUR 14.4

Malignant melanoma
ME1004h each
EUR 306
Description: Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores, replacing ME1004g

Malignant melanoma
ME1006 each
EUR 378
Description: Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage (AJCC 8th edition), 100 cases/ 100 cores (core size 1.0mm),replacing ME1004h

Human Melanoma CAFs
CAF09 1,000,000 cells
EUR 1749.6

Melanoma tissue array
ME483 each
EUR 270
Description: Melanoma tissue array, including TNM and clinical stage, 48 cases/48 cores, replaced by ME483a

Melanoma (gp100) Protein
20-abx263540
  • EUR 994.80
  • EUR 493.20
  • EUR 644.40
  • 10 ug
  • 2 µg
  • 5 ug

Melanoma Antibody / PNL2
V3071-100UG 100 ug
EUR 349.3
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.

Melanoma Antibody / PNL2
V3071-20UG 20 ug
EUR 153.3
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.

Melanoma Antibody / PNL2
V3071IHC-7ML 7 ml
EUR 349.3
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.

Melanoma Antibody / PNL2
V3071SAF-100UG 100 ug
EUR 349.3
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.

Primary UTI Agar
MED1334 EACH
EUR 691.2

Melanoma, 48 cases (1.5mm)
MEL961 1
EUR 372
Description: Melanoma tissue array containing 12 cases of normal epithelium, nevus and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates.

Melanoma; Pan (Concentrate)
A00134-C 1 ml
EUR 811.2

Melanoma; Pan (Concentrate)
A00134-C.1 0.1 ml
EUR 165.6

Primary UTI Opaque
MED1272 PK10
EUR 15.6

GFP-HUVEC (Primary)
P0027003 One Frozen vial
EUR 1066

TnI (Primary) Antibody
abx018056-100ug 100 ug
EUR 410.4

Primary Human Neurons
HNC001 300,000 Cyroperserved Cells
EUR 1467.6

Melanoma (skin cancer) Exosome
P141-MN - Ask for price

Melanoma Marker(PNL2) Antibody
BNC800894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC800894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC810894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC810894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC940894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC940894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC700894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC700894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC880894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC880894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC050894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC050894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC040894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC040894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC400894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC400894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCB0894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCB0894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCAP0894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCAP0894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCA0894-250 250uL
EUR 459.6
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCR0894-250 250uL
EUR 459.6
Description: Primary antibody against Melanoma Marker(PNL2), RPE conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCP0894-250 250uL
EUR 459.6
Description: Primary antibody against Melanoma Marker(PNL2), PerCP conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNUM0894-50 50uL
EUR 474
Description: Primary antibody against Melanoma Marker(PNL2), 1mg/mL

Melanoma Marker(PNL2) Antibody
BNCH0894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNCH0894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNUB0894-100 100uL
EUR 250.8
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL

Melanoma Marker(PNL2) Antibody
BNUB0894-500 500uL
EUR 549.6
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL

Melanoma Marker(PNL2) Antibody
BNC610894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC610894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF660R conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC550894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC550894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC430894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC430894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC680894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC680894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC470894-100 100uL
EUR 238.8
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL

Melanoma Marker(PNL2) Antibody
BNC470894-500 500uL
EUR 652.8
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL

PMEL17 / Melanoma gp100 Antibody
V3472-100UG 100 ug
EUR 349.3
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa).

PMEL17 / Melanoma gp100 Antibody
V3472-20UG 20 ug
EUR 153.3
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa).

PMEL17 / Melanoma gp100 Antibody
V3472IHC-7ML 7 ml
EUR 349.3
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa).

PMEL17 / Melanoma gp100 Antibody
V3472SAF-100UG 100 ug
EUR 349.3
Description: The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa. By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This MAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. This MAb stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. This MAb also stains Angiomyolipoma (PEComa).

PMEL17 / Melanoma gp100 Antibody
V9078-100UG 100 ug
EUR 349.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma.

The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments.

PMEL17 / Melanoma gp100 Antibody
V9078-20UG 20 ug
EUR 153.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma.

The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments.

PMEL17 / Melanoma gp100 Antibody
V9078IHC-7ML 7 ml
EUR 349.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma.

The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments.

PMEL17 / Melanoma gp100 Antibody
V9078SAF-100UG 100 ug
EUR 349.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma.

The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments.

PMEL17 / Melanoma gp100 Antibody
V9079-100UG 100 ug
EUR 349.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation.

PMEL17 / Melanoma gp100 Antibody
V9079-20UG 20 ug
EUR 153.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation.

PMEL17 / Melanoma gp100 Antibody
V9079SAF-100UG 100 ug
EUR 349.3
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation.

PMEL17 / Melanoma gp100 Antibody
V3916-100UG 100 ug
EUR 349.3
Description: PMEL17/Melanoma gp100/SILV plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. [UniProt]

Melanoma (primary nd